High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

Paul J. Hengeveld(Erasmus MC), Mark‐David Levin(Albert Schweitzer Hospital), Lina van der Straten(Erasmus MC), Peter E. Westerweel(Albert Schweitzer Ziekenhuis), Henk‐Jan Boiten(Erasmus MC), Melissa Rijken(Erasmus MC Cancer Institute), Kirsten J. Gussinklo(Erasmus MC Cancer Institute), Arnon P. Kater(Amsterdam University Medical Centers), P. Martijn Kolijn(Erasmus MC), Jeroen Demmers(Erasmus MC), Peter J.M. Valk(Erasmus MC Cancer Institute), Anton W. Langerak(Erasmus MC), Wouter Doff(Erasmus MC), Jorn L. J. C. Assmann(Erasmus MC), Julie Dubois(University of Fribourg)

Blood

November 15, 2022

10.1182/blood-2022-158881

Cited by 0

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936

|Leukemia|2003|3k

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

|Cancer Cell|2010|2.7k

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

|Nature|2013|2.1k

A 17-gene stemness score for rapid determination of risk in acute leukaemia

|Nature|2016|916

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

|New England Journal of Medicine|2018|907